Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma

The Journal of Dermatology, 05/10/2012

Vorinostat was well tolerated at a dose of 400 mg p.o. once daily and showed potential efficacy in Japanese patients with cutaneous T–cell lymphoma (CTCL), warranting further investigation.

Print Article Summary Cat 2 CME Report